BPC-157 vs GHK-Cu: Cost and Access Head-to-Head
At a glance
- FDA-approved drugs containing either peptide / None [2][3]
- Topical GHK-Cu / Cosmetic; no FDA premarket approval [1]
- Non-injectable GHK-Cu compounding / Category 1, under evaluation [2]
- Injectable GHK-Cu / 'Nominated but withdrawn'; immunogenicity concern [4]
- BPC-157 compounding / In none of FDA's three categories [2]
- BPC-157 policy status / Draft HHS enforcement discretion, October 2026; not an approval [5][6]
- WADA / BPC-157 named in S0; GHK-Cu not named [7]
Is either peptide an approved drug?
No. No FDA-approved drug contains BPC-157, and FDA's July 2026 review found no approved product containing it in any country it searched [3]. No FDA-approved drug is known to contain GHK-Cu [2].
A different copper compound, copper histidinate (Zycubo), was approved on January 12, 2026 for Menkes disease in children [2][8]. It is not GHK-Cu.
Access route one: topical GHK-Cu goes to market as a cosmetic
Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold [1]. Copper peptide serums and creams can be sold as cosmetics without FDA premarket approval. Products marketed to treat disease or affect the body's structure or function may instead be regulated as drugs, since FDA decides cosmetic versus drug by intended use [1].
An injectable GHK-Cu product is not a cosmetic, and it is not FDA-approved [1].
Access route two: what FDA's compounding lists say
Non-injectable GHK-Cu. On FDA's list of bulk substances nominated for state-licensed pharmacies and physicians, 'GHK-Cu (except for injectable routes of administration)' sits in category 1 [2]. Category 1 is the group FDA says it generally does not intend to take action against compounders for, provided the conditions in its guidance are met [9]. Non-injectable GHK-Cu was removed from category 1 on April 22, 2026 when the nominations were withdrawn, then added back after a nominator clarified on May 5, 2026 that only the injectable route had been withdrawn; the list was updated May 14, 2026 [2]. FDA has announced that it intends to consult its Pharmacy Compounding Advisory Committee about whether to include GHK-Cu on the pharmacy bulks list before the end of February 2027, and no vote has taken place [2].
Injectable GHK-Cu. FDA's page on bulk substances that may present significant safety risks, with content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' in its 'nominated but withdrawn' table [4]. FDA's stated concern is immunogenicity from the potential for aggregation and peptide-related impurities, with limited human data to inform safety considerations [4]. Injectable GHK-Cu is not in category 1 and is not in any category on FDA's current list [2].
BPC-157. On the same nominated list, updated May 14, 2026, BPC-157 appears in none of the three categories, so FDA's category 1 policy does not cover it [2]. It was in category 2, the significant-safety-risk group, from September 2023 until April 22, 2026, when the nominating groups withdrew and it moved to the 'nominated but withdrawn' table; that removal was not a finding of safety [4]. FDA's stated concerns remain on that page: possible immunogenicity for certain routes of administration, peptide-related impurities and problems characterizing the active ingredient, and the statements that FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' and 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [4].
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation [10]. The vote is advisory only — advisory committees make non-binding recommendations — and BPC-157 is not on the list; adding a substance takes notice-and-comment rulemaking [10][9]. FDA's own reviewers had proposed that it not be listed, citing poor chemical characterization, little information on safety and immunogenicity, insufficient evidence that it works for ulcerative colitis (the use FDA evaluated), and several approved drugs that already treat that condition [3].
The October 2026 HHS draft policy names BPC-157, not GHK-Cu
On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy for compounding with six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [6][5]. It was scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [6]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [5].
The conditions for BPC-157 cover BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard; a label reading 'This is a compounded drug product. Not for resale.'; a patient-specific prescription; reporting of serious adverse events and quality problems to FDA MedWatch; an FDA 510(k)-cleared syringe as the only co-packaged device; and documentation of adequate bioavailability for oral forms [5].
The draft policy is not an approval and does not put BPC-157 on any list. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it [6]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [5], and BPC-157 is not on FDA's list for outsourcing facilities, updated March 21, 2025 [11]. GHK-Cu is not among the six peptides [5], and it is not on the outsourcing facility list either [11].
Compounded and research-labeled products
Compounded drugs are not FDA-approved: FDA does not verify their safety, effectiveness or quality before they are marketed [12].
Research-labeled products are a separate market. FDA noted websites selling BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use', and stated that those products are not FDA-approved drugs [3].
Side by side
| Question | BPC-157 | GHK-Cu |
|---|---|---|
| FDA-approved drug? | No [3] | No [2] |
| Direct-to-consumer products described | Unapproved capsules, injections, oral sprays and nasal sprays [3] | Topical cosmetic creams and serums [1] |
| FDA nominated-bulk list, updated May 14, 2026 | None of the three categories [2] | Non-injectable: category 1 [2] |
| FDA significant-safety-risk page | In the 'nominated but withdrawn' table [4] | Injectable route only: 'nominated but withdrawn' table [4] |
| October 2026 HHS draft policy | Included, with conditions [5] | Not included [5] |
| WADA 2026 and 2027 Lists | Named in S0 [7][13] | Not named on either list [7][14] |
Sport: only one of the two is named by WADA
WADA's Prohibited List names BPC-157 in S0, the class covering substances with no current approval by any governmental regulatory health authority for human therapeutic use. The class description says it includes 'but not limited to BPC-157', and the substance is prohibited at all times, in and out of competition [7]. It was first named in the 2022 List and stays named in the 2027 List, which takes effect January 1, 2027 [15][13].
GHK-Cu is not named on the 2026 or 2027 WADA Lists, but WADA's 2027 explanatory notes state that peptides not specifically named may still be prohibited [7][14].
What FDA says about safety of the compounded forms
For injectable GHK-Cu, FDA's stated position is that there are 'limited data in humans to inform safety-related considerations' [4].
For BPC-157, FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' and found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin [3]. Its search of the adverse-event database through December 4, 2025 turned up three reports, all for injectable BPC-157: injection-site redness and swelling for nine days in a patient who also used compounded thymosin, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product. FDA said it cannot tell whether BPC-157 caused these [3]. In 28-day intramuscular animal studies FDA reviewed, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [3].
Frequently asked questions
Is BPC-157 FDA-approved?
Can you buy GHK-Cu without a prescription?
How does access differ between the two peptides?
Is BPC-157 banned in sport?
Does the October 2026 HHS policy make BPC-157 legal?
References
Show all 15 referencesHide references
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Compounding and the FDA: Questions and Answers | FDA.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- World Anti-Doping Agency.